A mission-critical “lab-to-production” franchise at a distressed valuation—if Revival restores margins and growth, AVTR can re-rate materially; if not, leverage and competition can turn it into a value trap.
Overview
Avantor is a scaled life-sciences enabler that combines VWR’s global distribution reach with proprietary, high-purity manufacturing to serve biopharma, healthcare, academia/government labs, and advanced technology customers. Its differentiated “Lab-to-Production” model spans discovery to commercial manufacturing, supporting 300,000+ customer locations in 180 countries. Revenue is structurally recurring (about 85% consumables/services) split between Laboratory Solutions (~$4.4B in 2025) and the higher-margin Bioscience Production segment (~$2.15B). 2025 results reflect post-pandemic normalization, customer destocking, and portfolio actions, pressuring margins and earnings. Management’s Revival program is the central catalyst intended to rebuild growth and expand EBITDA margins back toward historical levels through cost savings, operational fixes, and a renewed VWR go-to-market.